trending Market Intelligence /marketintelligence/en/news-insights/trending/l1esrck1wjasmvh6g10dgq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA approves Mylan's generic ADHD drug

AT&T To Use Wireless Subs To Create Buzz For HBO

Municipal CUSIP Requests On Pace For Record Year, Thanks To October Issuance Surge

Creating an Efficient Enterprise Wide Credit Risk Management System for a Leading Energy Company

Power and Gas M&A Symposium - 2019 Highlights


US FDA approves Mylan's generic ADHD drug

Mylan NV received final approval from the U.S. FDA for its abbreviated new drug application for Methylphenidate Hydrochloride extended-release tablets, a generic version of Janssen Pharmaceuticals Inc.'s Concerta tablets.

The product is intended for the treatment of attention deficit hyperactivity disorder.

Mylan also launched the generic product in the U.S. Methylphenidate Hydrochloride extended-release tablets had sales of about $1.59 billion in the U.S. for the 12 months ending Oct. 31, according to data from IMS Health.